EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Reference library Primary sources checked October 2026 Illustrative calculators

Toxicology and risk assessment

The terms, test guidelines and arithmetic that turn a toxicity study into an intake limit or a cancer risk estimate, and the methods that show how uncertain that number is.

10−6 to 10−4Excess lifetime cancer risk range for acceptable exposure at Superfund sites (40 CFR 300.430)
10,000Margin of exposure, based on an animal BMDL10, that EFSA calls of low concern for a genotoxic carcinogen
80 kgEPA default adult body weight since 2014, replacing 70 kg (OSWER Directive 9200.1-120)
135Agents in IARC Group 1, carcinogenic to humans (IARC list updated July 3, 2026)

Status. EUTECNIQ is in formation and has run no studies or assessments. The calculators on this page do illustrative arithmetic with stated inputs; they are not a safety assessment of any product.

Related: Course 9, Toxicology and dose · Toxicology programs · NDIN strategy and dossiers

Definitions

Dose–response vocabulary

Median values (LD50, LC50, EC50, IC50) locate the middle of a dose–response curve. Regulatory limits start lower, at a point of departure near the low end of the observed range: a NOAEL, a LOAEL or a BMDL. The definitions below are quoted from the IUPAC toxicology glossary and EPA's IRIS glossary.

Effect-level terms with their source definitions
TermDefinition (quoted)Usual unitSource
LD50, median lethal dose“Statistically derived median dose of a chemical or physical agent (radiation) expected to kill 50% of organisms in a given population under a defined set of conditions.”mg/kg body weightIUPAC 2007
LC50, median lethal concentration“Statistically derived median concentration of a substance in an environmental medium expected to kill 50% of organisms in a given population under a defined set of conditions.”mg/L air or water; ppmV for gasesIUPAC 2007
EC50, median effective concentration“Statistically derived median concentration of a substance in an environmental medium expected to produce a certain effect in 50% of test organisms in a given population under a defined set of conditions.”mg/L, µMIUPAC 2007
ED50, median effective doseMedian dose “expected to produce a certain effect in 50% of test organisms in a given population or to produce a half-maximal effect in a biological system under a defined set of conditions.”mg/kgIUPAC 2007
IC50“the median concentration that causes 50% inhibition” of a given system.µM, µg/mLIUPAC 2007
NOAEL“The highest exposure level at which there are no biologically significant increases in the frequency or severity of adverse effect between the exposed population and its appropriate control; some effects may be produced at this level, but they are not considered adverse or precursors of adverse effects.”mg/kg-dayEPA IRIS
LOAEL“The lowest exposure level at which there are biologically significant increases in frequency or severity of adverse effects between the exposed population and its appropriate control group.”mg/kg-dayEPA IRIS
BMD“A dose or concentration that produces a predetermined change in response rate of an adverse effect (called the benchmark response or BMR) compared to background.” For quantal data EPA's standard reporting BMR is a 10% extra risk (BMD10).mg/kg-dayEPA IRIS; EPA 2012
BMDL“A statistical lower confidence limit on the dose or concentration at the BMD or BMC, respectively.” EPA reports a one-sided 95% limit.mg/kg-dayEPA IRIS; EPA 2012
Point of departure“The dose-response point that marks the beginning of a low-dose extrapolation.” It can be a BMDL, a NOAEL or a LOAEL.mg/kg-dayEPA IRIS

Sources: Duffus JH, Nordberg M, Templeton DM. Glossary of terms used in toxicology, 2nd edition (IUPAC Recommendations 2007), NLM archived text; U.S. EPA IRIS Glossary (updated April 13, 2026); U.S. EPA Benchmark Dose Technical Guidance, EPA/100/R-12/001 (June 2012).

Intake limits

From point of departure to limit

Each framework divides a point of departure by factors for the gaps between the study and people. The names differ by regulator: PDE (ICH, pharmaceutical impurities), ADI (food additives, and FDA's NDI guidance), TDI (contaminants), RfD (EPA). The factors differ too, so one study can yield several limits.

Intake-limit terms and how each is calculated
TermDefinitionCalculationSource
PDE, permitted daily exposure“The maximum acceptable intake per day of residual solvent in pharmaceutical products.”NO(A)EL × 50 kg ÷ (F1 × F2 × F3 × F4 × F5), in mg/dayICH Q3C(R9)
ADI, acceptable daily intake“An estimate of the amount of a substance in food or drinking water that can be consumed daily over a lifetime without presenting an appreciable risk to health.”FDA NDI guidance: NOAEL ÷ combined safety factor (usually 100 for a chronic study, 1,000 from two subchronic studies, 2,000 from one rodent subchronic study)EFSA glossary; FDA 2026, IX.5
TDI, tolerable daily intake“An estimate of the amount of a substance in food or drinking water which is not added deliberately (e.g. contaminants) and which can be consumed over a lifetime without presenting an appreciable risk to health.”Reference point ÷ uncertainty factorsEFSA glossary
RfD, reference dose“An estimate (with uncertainty spanning perhaps an order of magnitude) of a daily oral exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime.”Point of departure ÷ UFsEPA IRIS
UF, uncertainty factor“One of several, generally 10-fold, default factors”: human variability, animal to human, subchronic to chronic, LOAEL to NOAEL, incomplete database.Multiplied togetherEPA IRIS
Margin of safety (FDA NDIN)“a measure of how close the EDI is to the NOAEL”; the EDI is the highest total daily intake under the proposed conditions of use.NOAEL ÷ EDI; FDA also asks for EDI ÷ ADI ≤ 1FDA 2026, IX.2, IX.6
ICH Q3C modifying factors F1 to F5 for the PDE equation
FactorAccounts forValues in ICH Q3C(R9), Appendix 3
F1Extrapolation between species5 rat; 12 mouse; 2 dog; 2.5 rabbit; 3 monkey; 10 other animals
F2Variability between individuals10
F3Short-term exposure studies1 for at least half a lifetime (1 year rodents or rabbits); 2 for a 6-month rodent study; 5 for a 3-month rodent study; 10 for shorter studies
F4Severe toxicityReproductive studies: 1 fetal toxicity with maternal toxicity; 5 fetal toxicity without it; 5 teratogenic effect with maternal toxicity; 10 teratogenic effect without it
F5No-effect level not establishedUp to 10 when only a LOEL is available

Sources: ICH Q3C(R9), Appendix 3, eq. (1) and the 50 kg body weight convention (EMA/CHMP/ICH/82260/2006, April 2024); EFSA glossary (ADI, TDI); U.S. EPA IRIS Glossary; FDA final guidance, NDI Notifications and Related Issues: Identity and Safety Information About the NDI (October 2026), Section IX.

The same hypothetical study gives a BMDL10 of 11.8 and a NOAEL of 30 mg/kg-day, and three frameworks turn them into limits that differ several-foldHypothetical data, computed fit
A hypothetical 90-day rat study with 20 animals per group at 0, 10, 30, 100 and 300 mg/kg body weight per day and 0, 1, 2, 7 and 15 animals with the effect. A fitted log-logistic curve gives a BMD10 of 26.8 and a BMDL10 of 11.8 mg/kg per day; a Fisher exact test gives a NOAEL of 30 and a LOAEL of 100. The right panel derives three intake limits from the NOAEL or BMDL: an ICH Q3C permitted daily exposure of 6 mg per day, an FDA NDIN acceptable daily intake of 0.015 mg/kg per day (1.05 mg per day at 70 kg), and a reference dose of 0.0118 mg/kg per day with three tenfold factors.
Hypothetical quantal data. BMR and BMDL convention: U.S. EPA Benchmark Dose Technical Guidance (EPA/100/R-12/001, 2012). PDE: ICH Q3C(R9), eq. (1). ADI: FDA final guidance on NDI identity and safety information (October 2026), Section IX.5. RfD factors: EPA IRIS glossary. Illustration by EUTECNIQ. Full-size SVG
Margins and thresholds

Margin of exposure and TTC

For a substance that is both genotoxic and carcinogenic, EFSA divides the BMDL10 by the estimated exposure; a margin of exposure of 10,000 or more, “if it is based on the BMDL10 from an animal study,” is of low concern. When a substance has no toxicity data, the threshold of toxicological concern (TTC) uses its chemical structure to set an exposure below which the probability of harm is very low.

TTC values by structural class (EFSA 2019, from Kroes et al. 2004)
ClassWhat the class contains (EFSA 2019, Table 1, abridged)µg/person per dayµg/kg bw per day
Potential DNA-reactive mutagens or carcinogensStructural alerts for genotoxicity, on the weight of evidence0.150.0025
Organophosphates and carbamatesOrganophosphate or carbamate structures180.3
Cramer Class IIIStructures that “permit no strong initial presumption of safety or may even suggest significant toxicity or have reactive functional groups”901.5
Cramer Class IILess innocuous than Class I, without the features of Class III5409.0
Cramer Class I“Simple chemical structures and for which efficient modes of metabolism exist, suggesting a low order of oral toxicity”1,80030

The µg/kg bw values are the per-person values divided by 60 kg, the body weight Munro et al. used. Not applicable to inorganic substances, proteins, nanomaterials, radioactive substances, organosilicon substances, metals, high-potency carcinogens (aflatoxin-like, azoxy- or N-nitroso substances, benzidines), steroids and bioaccumulating substances. Sources: EFSA Scientific Committee, Guidance on the use of the TTC approach in food safety assessment, EFSA J 2019;17(6):5708; Kroes R et al., Food Chem Toxicol 2004;42:65–83; Cramer GM, Ford RA, Hall RL, Food Cosmet Toxicol 1978;16:255–276; EFSA Scientific Committee, EFSA J 2012;10(3):2578 (MOE statement).

Worked example: margin of exposure for pyrrolizidine alkaloids in a dried herbal infusion (hypothetical consumption)
PA content of the dried herbDried herb, g/dayPA intake, µg/dayExposure, µg/kg bw per dayMOE = 237 ÷ exposureAgainst 10,000
200 µg/kg (EU maximum, dried herbal infusions)20.40.0057≈ 41,500Above
200 µg/kg61.20.0171≈ 13,800Above
400 µg/kg (EU maximum, e.g. rooibos, chamomile, peppermint)62.40.0343≈ 6,900Below

Reference point: BMDL10 237 µg/kg bw per day, derived from riddelliine data (EFSA CONTAM Panel, EFSA J 2017;15(7):4908). Maximum levels: Commission Regulation (EU) 2023/915 (sum of 21 PAs plus 14 co-eluting PAs). Illustrative assumptions: 70 kg adult (EFSA default), all PAs transferred to the infusion, daily lifetime use. Product within the legal maximum can still give an MOE below 10,000 at high consumption.

Hazard classification

GHS acute oral toxicity categories

The UN Globally Harmonized System sorts substances into five acute toxicity categories by an acute toxicity estimate (ATE), which is the LD50 where one exists. Category 5 marks relatively low hazard that may matter for vulnerable populations; GHS discourages animal testing in that range.

The four OECD fixed doses sit exactly on the GHS category boundariesUN GHS Rev.10; OECD TG 420, 423
GHS acute oral toxicity categories on a logarithmic dose axis from 1 to 10,000 mg/kg body weight, with the four fixed doses used by OECD Test Guidelines 420 and 423 at the category boundariesCategory 1: oral ATE ≤ 5 mg/kg bwCategory 1≤ 5Category 2: oral ATE 5–50 mg/kg bwCategory 25–50Category 3: oral ATE 50–300 mg/kg bwCategory 350–300Category 4: oral ATE 300–2,000 mg/kg bwCategory 4300–2,000Category 5: oral ATE 2,000–5,000 mg/kg bwCategory 52,000–5,000NotclassifiedOral acute toxicity estimate (ATE), mg/kg body weight, log scale1101001,00010,000Fixed dose 5 mg/kg5Fixed dose 50 mg/kg50Fixed dose 300 mg/kg300Fixed dose 2,000 mg/kg2,000Fixed doses of OECD TG 420 and 423, mg/kg body weightThe fixed doses sit on the category boundaries, so a study at these doses assigns a category without estimating an LD50. TG 420 uses 5,000 mg/kg only inexceptional cases.GHS acute oral toxicity categories on a logarithmic dose axis from 1 to 10,000 mg/kg body weight, with the four fixed doses used by OECD Test Guidelines 420 and 423 at the category boundariesCategory 1: oral ATE ≤ 5 mg/kg bw1Category 2: oral ATE 5–50 mg/kg bw2Category 3: oral ATE 50–300 mg/kg bw3Category 4: oral ATE 300–2,000 mg/kg bw4Category 5: oral ATE 2,000–5,000 mg/kg bw5NCOral ATE, mg/kg bw (log scale)1101001,00010,000Fixed dose 5 mg/kg5Fixed dose 50 mg/kg50Fixed dose 300 mg/kg300Fixed dose 2,000 mg/kg2,000Fixed doses, OECD TG 420 and 423Category, oral ATE in mg/kg: 1 ≤ 5; 2 5–50; 3 50–300; 4300–2,000; 5 2,000–5,000; NC not classified.The fixed doses sit on the category boundaries, so astudy at these doses assigns a category withoutestimating an LD50. TG 420 uses 5,000 mg/kg only inexceptional cases.
UN GHS, tenth revised edition (ST/SG/AC.10/30/Rev.10, 2023), Table 3.1.1; OECD Test Guidelines 420 and 423.
GHS Table 3.1.1 (oral row) and Table 3.1.3 label elements
CategoryOral ATE, mg/kg bwSymbolSignal wordHazard statement
1ATE ≤ 5Skull and crossbonesDangerFatal if swallowed
25 < ATE ≤ 50Skull and crossbonesDangerFatal if swallowed
350 < ATE ≤ 300Skull and crossbonesDangerToxic if swallowed
4300 < ATE ≤ 2,000Exclamation markWarningHarmful if swallowed
52,000 < ATE ≤ 5,000No symbolWarningMay be harmful if swallowed

Source: United Nations, Globally Harmonized System of Classification and Labeling of Chemicals, Rev.10 (New York and Geneva, 2023), Chapter 3.1, Tables 3.1.1 and 3.1.3 and note (g).

Test methods

OECD test guidelines

Safety studies follow the OECD Guidelines for the Testing of Chemicals, Section 4, which FDA's 2026 NDI guidance names as a source of safety protocols. TG 401, the classical LD50 test, was deleted on December 17, 2002; its three replacements estimate a hazard class or an LD50 with fewer animals.

OECD test guidelines most used in an ingredient safety program
TGStudyDesign points from the guidelineCurrent version
Acute oral toxicity
420Fixed dose procedureFixed doses 5, 50, 300, 2,000 mg/kg; usually females, 5 per step; endpoint is evident toxicity rather than deathOECD Publishing
423Acute toxic class methodThree animals per step; starting dose from 5, 50, 300, 2,000 mg/kg (300 when nothing is known); limit test at 2,000 mg/kg with six animalsAdopted Dec 17, 2001
425Up-and-down procedureOne animal at a time, about 48 h apart; dose down after a death, up after survival; LD50 with a confidence intervalPublished Jun 29, 2022
Repeated dose
40728-day oral, rodentsAt least 10 animals (5 per sex) per dose; limit test at 1,000 mg/kg bw/dayAdopted Jun 25, 2025
40890-day oral, rodentsAt least 20 animals (10 per sex) per dose; limit test at 1,000 mg/kg bw/dayAdopted Jun 25, 2025
452Chronic toxicityNormally 12 months; at least 20 rodents per sex per groupAdopted Jun 25, 2018
451CarcinogenicityNormally 24 months in rodents; at least 50 animals per sex per groupAdopted Jun 25, 2018
Genotoxicity
471Bacterial reverse mutation (Ames)At least five bacterial strains, including four S. Typhimurium strains; at least five analysable concentrationsAdopted Jul 21, 1997; corrected Jun 26, 2020
473In vitro mammalian chromosomal aberrationAt least 300 well-spread metaphases scored per concentration and controlAdopted Sep 26, 2014
487In vitro mammalian cell micronucleusMicronuclei scored in at least 2,000 cells per concentrationAdopted Jul 19, 2016; corrected Jul 4, 2023
474Mammalian erythrocyte micronucleus (in vivo)At least 4,000 immature erythrocytes scored per animalAdopted Jul 29, 2016
Reproductive and developmental
414Prenatal developmental toxicityRat and rabbit preferred; dosing from implantation to the day before scheduled kill; about 20 females with implantation sites per groupPublished Jun 26, 2018
416Two-generation reproductionParents dosed through mating, pregnancy and weaning of F1; F1 dosed to produce F2; at least 20 pregnant females per groupPublished Jan 21, 2001
443Extended one-generation reproductive toxicityAt least 20 pregnant females per dose group; F1 cohorts for reproductive, developmental neurotoxicity and developmental immunotoxicity endpointsAdopted Jun 25, 2025

Sources: OECD Test Guidelines 407, 408, 423, 443, 451, 452, 471, 473, 474 and 487 (guideline PDFs, adoption and correction dates from their cover pages); OECD publication pages for TG 414, 416, 420 and 425. FDA final guidance (October 2026), Section VII. TG 401 deletion date: OECD publication page for Test No. 401.

Study quality and use

GLP and the NDIN safety narrative

Good Laboratory Practice is “a quality system concerned with the organisational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived and reported” (OECD). In the United States, 21 CFR Part 58 applies to nonclinical studies supporting applications for FDA research or marketing permits. Its scope lists food and color additives, drugs, devices and biologics; dietary supplements are not named (see NDIN strategy).

What GLP regulates, and what FDA asks a safety narrative to contain
ElementRequirement or recommendationSource
Quality assurance unitMonitors each study; “entirely separate from and independent of the personnel engaged in the direction and conduct of that study”21 CFR 58.35
Written protocolEach study has an approved protocol stating its objectives and all methods21 CFR 58.120
Test article characterizationIdentity, strength, purity and composition determined21 CFR 58.105
Records and archivesRaw data, protocols, specimens and final reports retained in archives21 CFR 58.190, 58.195
Mutual Acceptance of DataData from OECD test guidelines and OECD GLP “shall be accepted in other Member countries”; principles revised and adopted November 26, 1997OECD C(81)30(Final); C(97)186/Final
Safety narrative: evidenceObjective evaluation of history of safe use, safety studies or both, and why they support a reasonable expectation of safetyFDA 2026, V.2
Safety narrative: intakeEstimated total daily intake, and effects of non-dietary ingredients that alter the safety profile, for example by raising bioavailabilityFDA 2026, V.2
Safety narrative: related test articlesQualitative and quantitative comparison of each tested material with the NDI; whole-herb intake compared with extract intakeFDA 2026, V.2
Safety narrative: calculationsOne justified NOAEL from the most sensitive species; margin of safety; ADI; EDI/ADI ≤ 1FDA 2026, IX

Sources: eCFR, 21 CFR Part 58 (up to date as of October 26, 2026), §§ 58.1, 58.35, 58.105, 58.120, 58.190, 58.195; OECD, Principles on Good Laboratory Practice (as revised in 1997), ENV/MC/CHEM(98)17, Section 2.1; FDA final guidance, NDI identity and safety information (October 2026), Sections V and IX.

Carcinogen classification

IARC carcinogen groups

IARC classifies the strength of evidence that an agent can cause cancer, not the size of the risk at a given exposure. In its words, “probably” and “possibly” carcinogenic “have no quantitative significance.” Group 3 “is not a determination of non-carcinogenicity or overall safety.” There is no “not carcinogenic” group; a well-studied agent may instead be described as “without evidence of carcinogenic activity.”

IARC Monographs groups (Preamble, 2019) and number of agents classified
GroupNameUsual basis (Preamble Table 4, simplified)Agents
1Carcinogenic to humansSufficient evidence in humans; or strong mechanistic evidence in exposed humans plus sufficient evidence in animals135
2AProbably carcinogenic to humansAt least two of: limited evidence in humans, sufficient evidence in animals, strong mechanistic evidence, one of them involving humans or human cells98
2BPossibly carcinogenic to humansOnly one of those three evaluations329
3Not classifiable as to carcinogenicity to humansAll other situations498

Sources: IARC Monographs Preamble (amended January 2019), Section 6(d), “Overall evaluation,” and Table 4; IARC, Agents classified by the IARC Monographs, Volumes 1–, list last updated July 3, 2026 (counts as shown on that page).

Cancer risk

Cancer risk arithmetic

EPA's Superfund method averages intake over a lifetime and multiplies by a slope factor, an upper-bound estimate of risk per mg/kg-day. The result is an upper-bound excess lifetime cancer risk, not a predicted number of cases. The linear equation holds below a risk of 0.01; above it RAGS uses Risk = 1 − exp(−CDI × SF).

Oral (RAGS Part A, Exhibit 6-11 and Section 8.2.1)CDI = C × IR × EF × EDBW × AT  ELCR = CDI × SF
Inhalation (RAGS Part F, Equations 6 and 11)EC = CA × ET × EF × EDAT  Risk = IUR × EC
EPA standard default exposure factors, 2014 update (selected rows)
SymbolFactorPrevious default2014 defaultBasis given by EPA
BWaAdult body weight, kg7080EFH 2011, Table 8-3, adults 21–78
BWcChild body weight, kg1515Birth to <6 years
IRWaAdult drinking water, L/day22.590th percentile, consumers only
IRWcChild drinking water, L/day10.78Weighted 90th percentile, birth to <6 years
IRSaAdult soil ingestion, mg/day1001001991 value retained
EFr / EFwExposure frequency, resident / worker, days/yr350 / 250350 / 250Not provided in EFH 2011
EDr / EDwExposure duration, resident / worker, yr30 / 2526 / 25Resident: 90th percentile residence time
ETra / ETwAir exposure time, resident / worker, h/day24 / 824 / 8Whole day / work day
ATAveraging time for carcinogens70 years × 365 days/yearRAGS Part A convention

Sources: U.S. EPA, RAGS Volume I Part A, EPA/540/1-89/002 (December 1989), Exhibits 6-9 and 6-11 and Section 8.2.1; RAGS Part F, EPA-540-R-070-002 (January 2009), Equations 6 and 11; OSWER Directive 9200.1-120 (February 6, 2014), Attachment 1; Exposure Factors Handbook 2011; 40 CFR 300.430(e)(2)(i)(A)(2).

Interactive calculator Change the inputs and the result updates. An educational simulation with stated inputs.

Lifetime-averaged dose and excess lifetime cancer riskIllustrative arithmetic
CDI, mg/kg-day–
Excess lifetime cancer risk–
Against 10−6 to 10−4–

Defaults: EPA 2014 residential factors and a hypothetical concentration and slope factor (1 (mg/kg-day)−1) or unit risk (10−6 per µg/m³); no real substance is implied. Equations: RAGS Part A (1989) and Part F (2009). Illustrative arithmetic, not a risk assessment.
The calculator's default lands at 1.1 × 10−5, inside the Superfund range40 CFR 300.430; RAGS Part A
Excess lifetime cancer risk on a logarithmic scale from one in ten million to one in ten: the Superfund acceptable range from one in a million to one in ten thousand, and the risk of 0.01 above which RAGS Part A says the linear equation is not valid40 CFR 300.430(e)(2)(i)(A)(2): 10^-6 to 10^-4Above 0.01: use the one-hit equation (RAGS Part A, 8-11)10−7​10−6​10−5​10−4​10−3​10−2​10−1​Excess lifetime cancer risk (unitless probability), log scaleSuperfund range 10−6​ to 10−4​; 10−6​ is the point ofdepartureRisk above 0.01: linear equation notvalidCalculator default: 1.11e-05Calculator default 1.1 × 10−5​Default: hypothetical slope factor 1 (mg/kg-day)−1​; EPA 2014 residential defaults. Schematic scale only.Excess lifetime cancer risk on a logarithmic scale from one in ten million to one in ten: the Superfund acceptable range from one in a million to one in ten thousand, and the risk of 0.01 above which RAGS Part A says the linear equation is not valid40 CFR 300.430(e)(2)(i)(A)(2): 10^-6 to 10^-4Above 0.01: use the one-hit equation (RAGS Part A, 8-11)10−7​10−6​10−5​10−4​10−3​10−2​10−1​Excess lifetime cancer risk (unitless probability), logscaleSuperfund range 10−6​to 10−4​; 10−6​ is thepoint of departureRisk above 0.01 (right band): linear equation notvalidCalculator default: 1.11e-05Default 1.1 × 10−5​Default: hypothetical slope factor 1 (mg/kg-day)−1​; EPA2014 residential defaults. Schematic scale only.
40 CFR 300.430(e)(2)(i)(A)(2) (eCFR, October 2026); RAGS Part A, Section 8.2.1 (linear equation valid “below estimated risks of 0.01”). Default: (0.001 × 2.5 × 350 × 26) ÷ (80 × 70 × 365) = 1.11 × 10−5 mg/kg-day, times SF = 1.
Uncertainty, part 1

Gap analysis

A gap analysis lists what a safety conclusion needs, what evidence exists, and what would close each difference. FDA frames the central gap as the difference between historical and proposed conditions of use: the larger the increase in serving, frequency or duration, the more “other evidence of safety” it recommends (Appendix A).

Steps of a gap analysis for an ingredient safety dossier
StepQuestionWhere FDA's 2026 guidance addresses it
1What exactly is proposed: dose, frequency, duration, population?IV (conditions of use)
2Is the ingredient identified and specified, and are toxins of related plants addressed?IV (botanical identity, extracts, specifications)
3What history of use exists, at what intake, daily or intermittent?VI
4Is each cited test article the same as the ingredient? If not, compare qualitatively and quantitativelyV.2
5Which studies fill the remaining gap?VII; Appendix A
6Do the calculations close: margin of safety, ADI, EDI/ADI ≤ 1?IX
Worked template: a hypothetical botanical extract (Ingredient X, ethanolic leaf extract, 500 mg/day daily chronic; historical use: leaf infusion, intermittent)
Evidence elementHypothetical statusGapOption to close it
IdentityBinomial, plant part and voucher documented; HPTLC fingerprintNoneKeep the specification current
CompositionExtract ratio known; marker compounds not quantified in the historical infusionExtract and infusion cannot be compared quantitativelyMeasure markers in both; express exposure as marker intake
History of useIntermittent infusion use documented; intake estimatedProposed use is daily chronic, so history alone is insufficientStudies per Appendix A for intermittent history and daily chronic use
Genetic toxicityNo dataHazard not characterizedFDA battery: bacterial mutation (TG 471) and an in vitro mammalian test (FDA prefers the mouse lymphoma tk assay; TG 473 and 487 assess chromosomal damage), plus in vivo chromosomal damage (TG 474) when history is limited
Repeat-dose toxicityPublished 28-day study on a different extractTest article differs; no 90-day NOAEL90-day oral study (TG 408) on the extract as specified
Reproductive toxicityNot studiedRelevant only if labeled for pregnancy, lactation or childrenExclude those populations on the label, or study
Safety calculationsNot possible without a NOAELNo margin of safety or EDI/ADIRecalculate when the 90-day NOAEL is available

Steps and study options: FDA final guidance, NDI identity and safety information (October 2026), Sections IV–VII, IX and Appendix A. Ingredient X and its status are hypothetical. FDA notes that not every listed study is always recommended and that the choice depends on the gap.

Uncertainty, part 2

Sensitivity analysis

One-way analysis moves one input at a time and reads the change in output; sorted by swing, the bars form a tornado chart. It misses interactions. Global, variance-based analysis apportions the output variance among inputs: the first-order Sobol index Si is the share from input i alone, and the total index STi adds its interactions. EPA's 1997 policy asks that sensitivity results be presented and discussed.

In the toy exposure model, concentration drives the spread; body weight barely moves itComputed from stated assumptions
Tornado chart and Sobol indices for the toy exposure model: concentration moves the dose most, then intake, then body weight; part of the variance comes from interactions between inputsOne-way sensitivity: each bar spans the dose with one input at its 5th and 95th percentile, others at their mediansConstituent concentration0.016 to 0.156 mg/gConstituent concentration low end: dose 6.15e-04 mg/kg-dayConstituent concentration high end: dose 6.01e-03 mg/kg-day0.616.01Product intake1.38 to 6.5 g/dayProduct intake low end: dose 8.88e-04 mg/kg-dayProduct intake high end: dose 4.17e-03 mg/kg-day0.894.17Body weight54 to 113 kgBody weight low end: dose 1.33e-03 mg/kg-dayBody weight high end: dose 2.78e-03 mg/kg-day1.332.78Median dose 1.920.31310Dose D = C × IR / BW, µg/kg-day (log scale)Global sensitivity: share of Var(D) explained (Sobol indices)ConcentrationC: total index 0.722 (seeded Saltelli check 0.716)C: first-order index 0.551 (seeded Saltelli check 0.594)0.55 / 0.72IntakeIR: total index 0.375 (seeded Saltelli check 0.369)IR: first-order index 0.221 (seeded Saltelli check 0.224)0.22 / 0.38Body weightBW: total index 0.092 (seeded Saltelli check 0.094)BW: first-order index 0.046 (seeded Saltelli check 0.047)0.05 / 0.09Dark bar: first-order index Si​. Light bar: total index STi​, which adds interactions. Values: Si​ / STi​.Tornado chart and Sobol indices for the toy exposure model: concentration moves the dose most, then intake, then body weight; part of the variance comes from interactions between inputsOne-way: each bar spans the dose with one inputat P5 and P95, others at mediansConstituent concentration (mg/g): 0.016 to 0.156Constituent concentration low end: dose 6.15e-04 mg/kg-dayConstituent concentration high end: dose 6.01e-03 mg/kg-day0.616.01Product intake (g/day): 1.38 to 6.5Product intake low end: dose 8.88e-04 mg/kg-dayProduct intake high end: dose 4.17e-03 mg/kg-day0.894.17Body weight (kg): 54 to 113Body weight low end: dose 1.33e-03 mg/kg-dayBody weight high end: dose 2.78e-03 mg/kg-day1.332.78Median dose 1.920.31310Dose D = C × IR / BW, µg/kg-day (log scale)Global sensitivity: share of Var(D) explained(Sobol indices)CC: total index 0.722 (seeded Saltelli check 0.716)C: first-order index 0.551 (seeded Saltelli check 0.594)0.55 / 0.72IRIR: total index 0.375 (seeded Saltelli check 0.369)IR: first-order index 0.221 (seeded Saltelli check 0.224)0.22 / 0.38BWBW: total index 0.092 (seeded Saltelli check 0.094)BW: first-order index 0.046 (seeded Saltelli check 0.047)0.05 / 0.09Dark bar: first-order index Si​. Light bar: total index STi​,which adds interactions. Values: Si​ / STi​.
Toy model D = C × IR ÷ BW with independent lognormal inputs: C geometric mean 0.05 mg/g, geometric SD 2.0; IR 3 g/day, GSD 1.6; BW 78 kg, GSD 1.25 (arithmetic mean 80.0 kg, matching EFH 2011). Sobol indices in closed form, checked with a seeded Saltelli estimator (215 samples, seed 20261028). Sobol IM, Math Comput Simul 2001;55:271–280; Saltelli A et al., Comput Phys Commun 2010;181:259–270.
Sobol indices for the toy model, on the dose and on its logarithm
InputSi, doseSTi, doseSi = STi, log dose
Concentration, C0.5510.7220.640
Intake, IR0.2210.3750.294
Body weight, BW0.0460.0920.066

On the log scale the model is additive (ln D = ln C + ln IR − ln BW), so each index is σi² ÷ Σσ² and there are no interactions. On the dose itself the first-order indices sum to 0.82; the remaining 0.18 comes from interactions. Computed values, not data.

Uncertainty, part 3

Monte Carlo simulation

Monte Carlo analysis replaces each point input with a distribution, samples them many times and reports the output distribution. EPA's 1997 Guiding Principles set the conditions: document every input distribution, report the random seed, check that the tail percentiles are stable, separate variability from uncertainty, and report the point estimate beside the distribution.

EPA conditions for a probabilistic risk assessment (EPA/630/R-97/001, March 1997), abridged
ConditionWhat it requires
1A problem formulation that names highly exposed or susceptible subpopulations
2Methods, models, data and assumptions documented so the analysis can be independently reproduced
3Sensitivity analysis presented and discussed
4Correlations and dependencies between inputs discussed and accounted for
5Each input and output distribution shown, with variability and uncertainty separated where possible
6Numerical stability of the central tendency and the tail presented
7Deterministic point estimates reported for comparison

Source: U.S. EPA Risk Assessment Forum, Guiding Principles for Monte Carlo Analysis, EPA/630/R-97/001 (March 1997), conditions 1–7 and Principle 9 (“Random number seeds should always be recorded”).

Interactive calculator Change the inputs and the result updates. An educational simulation with stated inputs.

Distribution of the daily dose D = C × IR ÷ BWIllustrative simulation
P5, µg/kg-day–
Median–
Mean–
P95–
P99–
Point estimate (medians)–

Seeded pseudo-random generator (mulberry32) and Box–Muller normal deviates, so a seed always reproduces the same figure. Defaults are the toy inputs of the sensitivity section; the closed-form lognormal values are P5 0.46, median 1.92, mean 2.80, P95 8.00 and P99 14.4 µg/kg-day. Illustrative, not data on any product.
Proposed work

Where EUTECNIQ would work

EUTECNIQ would characterize ingredients analytically, run the gap analysis and safety calculations, and document exposure models with their distributions, seeds and sensitivity results. GLP toxicology would be placed with qualified contract laboratories. Proposed

Related pages: Toxicology programs · Course 9, Toxicology and dose · NDIN strategy and dossiers · Reference library

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.